Article
Infectious Diseases
James A. Karlowsky, Sibylle H. Lob, Fakhar Siddiqui, Brune Akrich, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Stephen P. Hawser, Daniel F. Sahm
Summary: The study found that most Pseudomonas aeruginosa isolates in Western Europe (93.3%) were susceptible to ceftolozane/tazobactam, indicating it as an important treatment option for multidrug-resistant infections.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Microbiology
James A. Karlowsky, Sibylle H. Lob, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Summary: The study demonstrates that C/T is effective in treating lower respiratory tract infections caused by MDR P. aeruginosa and other Gram-negative pathogens. Compared to comparator agents, C/T showed higher activity against P. aeruginosa and Enterobacterales isolates.
Article
Infectious Diseases
S. Alexander Winans, Richelle L. Guerrero-Wooley, Susie H. Park, Garret Hino, Steven C. Forland
Summary: Ceftolozane-tazobactam has been approved for treating multidrug-resistant Pseudomonas aeruginosa meningitis, with cerebrospinal fluid concentrations reaching 83% of serum levels. Combined with other antibiotics, treatment led to clearance of the organism from the patient's cerebrospinal fluid and significant reduction in inflammatory cells.
Article
Infectious Diseases
Christian M. Gill, David P. Nicolau, RACE PA Global Study Grp
Summary: This study evaluated the genotypic and ceftazidime/avibactam-susceptibility profiles of ceftolozane/tazobactam-non-susceptible, MBL-negative Pseudomonas aeruginosa. The results showed that ceftazidime/avibactam remained active against the majority of ceftolozane/tazobactam-non-susceptible, MBL-negative Pseudomonas aeruginosa.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Barbara Balandin, Daniel Ballesteros, Rafael Ruiz de Luna, Loreto Lopez-Vergara, Vicente Pintado, Milagros Sancho-Gonzalez, Cruz Soriano-Cuesta, Maria Jose Perez-Pedrero, Maria Jose Asensio-Martin, Inamculada Fernandez-Simon, Diego Rodriguez-Serrano, Alberto Silva, Marta Chicot, Reyes Iranzo, Fernando Martinez-Sagasti, Ana Royuela
Summary: This study assessed the efficacy of ceftolozane-tazobactam (C/T) in treating Pseudomonas aeruginosa infections in critically ill patients. Results showed that C/T was effective in treating severe infections, with outcomes mainly related to infection severity. High-dose C/T or combination therapy with other antibiotics did not show additional benefits.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Review
Public, Environmental & Occupational Health
Laura Puzniak, Ryan Dillon, Thomas Palmer, Hannah Collings, Ashley Enstone
Summary: The review shows that Ceftolozane/tazobactam (C/T) is effective in clinical practice for gram-negative infections, even in seriously ill patients with resistant pathogens. Comparative studies suggest that C/T is a successful alternative to standard of care (SoC), with similar or better outcomes compared to other regimens.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
(2021)
Article
Microbiology
Abigail M. Rubio, Ellen G. Kline, Chelsea E. Jones, Liang Chen, Barry N. Kreiswirth, M. Hong Nguyen, Cornelius J. Clancy, Vaughn S. Cooper, Ghady Haidar, Daria Van Tyne, Ryan K. Shields
Summary: In this study, we compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates before and after exposure to ceftolozane-tazobactam and found treatment-emergent mutations in the AmpC gene, which were associated with altered resistance patterns. However, some ceftolozane-tazobactam-resistant isolates with AmpC mutations remained susceptible to imipenem-relebactam.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Damien Fournier, Romain Carriere, Maxime Bour, Emilie Grisot, Pauline Triponney, Cedric Muller, Jerome Lemoine, Katy Jeannot, Patrick Plesiat
Summary: This study evaluated the resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam, identifying strains with various resistance genes and high production of cephalosporinase PDC. It also found mutations in regulatory genes and enzymes contributing to resistance, highlighting the importance of both intrinsic and transferable mechanisms in C/T-resistant P. aeruginosa.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
David L. Paterson, Matteo Bassetti, Mary Motyl, Matthew G. Johnson, Mariana Castanheira, Erin H. Jensen, Jennifer A. Huntington, Brian Yu, Dominik J. Wolf, Christopher J. Bruno
Summary: This study confirms the efficacy of ceftolozane/tazobactam in treating HABP/VABP involving ESBL-positive and/or AmpC-producing pathogens.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Microbiology
Jocelyn Qi-Min Teo, Jie Chong Lim, Cheng Yee Tang, Shannon Jing-Yi Lee, Si Hui Tan, James Heng-Chiak Sim, Rick Twee-Hee Ong, Andrea Lay-Hoon Kwa
Summary: This study analyzed 195 carbapenem-nonsusceptible Pseudomonas aeruginosa clinical isolates recovered in Singapore from 2009 to 2020, and found that resistance to ceftolozane/tazobactam was mainly mediated by beta-lactamases, especially metallo-beta-lactamases. The high resistance to C/T highlights its limited utility as an empirical agent in the region.
Article
Infectious Diseases
David P. Nicolau, Jan De Waele, Joseph L. Kuti, Luzelena Caro, Kajal B. Larson, Brian Yu, Elaine Gadzicki, Zhen Zeng, Elizabeth G. Rhee, Matthew L. Rizk
Summary: This study aimed to determine the adequacy of established ceftolozane/tazobactam dosing for patients with augmented renal clearance (ARC) and bacterial infection. The results showed that a 3 g C/T dose met pharmacodynamic targets for ceftolozane and tazobactam in patients with ARC, with mild to moderate treatment-emergent adverse events observed.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Review
Infectious Diseases
Marco Fiore, Antonio Corrente, Maria Caterina Pace, Aniello Alfieri, Vittorio Simeon, Mariachiara Ippolito, Antonino Giarratano, Andrea Cortegiani
Summary: According to this systematic review and meta-analysis, C/T combination therapy is more effective in treating severe infections compared to C/T monotherapy, resulting in a reduction in patient mortality. However, there were no significant differences between C/T combination therapy and C/T monotherapy in terms of clinical improvement and microbiological cure.
Article
Microbiology
Gabriel Cabot, Kihun Kim, Brian L. L. Mark, Antonio Oliver, Mazdak Khajehpour
Summary: Several mutations in Pseudomonas aeruginosa AmpC have led to higher resistance against ceftazidime and ceftolozane, and also make the bacteria evade inhibition by avibactam. Interestingly, these mutations also make the strains more susceptible to carbapenem. The loss of efficacy in hydrolyzing imipenem by the cephalosporin-resistant AmpC enzymes may be attributed to their increased flexibility and dynamics compared to the wild type.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Helio S. Sader, Cecilia G. Carvalhaes, Jennifer M. Streit, Timothy B. Doyle, Mariana Castanheira
Summary: This study evaluated the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against Pseudomonas aeruginosa and Klebsiella pneumoniae isolates, showing high susceptibility rates for these two drugs. However, limited activity was observed against ESBL and carbapenemase producers in Klebsiella pneumoniae.
MICROBIAL DRUG RESISTANCE
(2021)
Article
Infectious Diseases
James A. Karlowsky, Mark G. Wise, Tai-Chin Hsieh, Hung-Chi Lu, Wei-Ting Chen, Ming-Huei Cheng, Fakhar Siddiqui, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Summary: This study investigated the antibiotic resistance of Pseudomonas aeruginosa isolated from patient samples in Taiwan from 2012 to 2021, and found an increasing prevalence of carbapenem-resistant P. aeruginosa. The medical centers in northern Taiwan reported the highest percentage of carbapenem-resistant P. aeruginosa. However, ceftolozane/tazobactam showed high activity against P. aeruginosa, particularly carbapenem-resistant strains, since 2016.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Infectious Diseases
Mariana Castanheira, Timothy B. Doyle, Cory Hubler, Helio S. Sader, Rodrigo E. Mendes
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2020)
Article
Microbiology
Rodrigo E. Mendes, Paul R. Rhomberg, Troy Lister, Nicole Cotroneo, Thomas R. Parr, Mariana Castanheira
Summary: The study evaluated the activities of various antibiotics alone and in combination with SPR741 against E. coli and K. pneumoniae isolates, indicating that azithromycin-SPR741 and minocycline-SPR741 had the lowest MIC90 values. Furthermore, fusidic acid-SPR741 showed better inhibition against enzymatic MLS mechanisms.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Dee Shortridge, S. J. Ryan Arends, Jennifer M. Streit, Mariana Castanheira
Summary: The study analyzed the minocycline susceptibility of various Gram-negative pathogens and found that it can be a useful treatment option, especially for infections caused by Achromobacter and Stenotrophomonas maltophilia which showed the highest susceptibility to minocycline among the species studied.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Michael A. Pfaller, Dee Shortridge, Kelly A. Harris, Mark W. Garrison, C. Andrew DeRyke, Daryl D. DePestel, Pamela A. Moise, Helio S. Sader
Summary: This study reported on the activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa isolates from US ICUs, showing that ceftolozane-tazobactam had the greatest activity against resistant phenotypes and DTR isolates.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Helio S. Sader, Mariana Castanheira, Michael D. Huband, Dee Shortridge, Cecilia G. Carvalhaes, Rodrigo M. Mendes
Summary: In this study, Dalbavancin and comparators were susceptibility tested against Gram-positive bacteria using broth microdilution method. Dalbavancin demonstrated potent activity and broad spectrum against a variety of bacteria.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2022)
Article
Microbiology
Cecilia G. Carvalhaes, Abby L. Klauer, Paul R. Rhomberg, Michael A. Pfaller, Mariana Castanheira
Summary: Rezafungin is a new echinocandin with potent activity against candidemia and invasive candidiasis. It also shows activity against Aspergillus isolates. The new CLSI breakpoints are important for understanding the susceptibility of Candida spp. and rezafungin.
JOURNAL OF CLINICAL MICROBIOLOGY
(2022)
Article
Infectious Diseases
Michael A. Pfaller, Cecilia G. Carvalhaes, Sean DeVries, Paul R. Rhomberg, Mariana Castanheira
Summary: This study analyzed the prevalence and susceptibility of invasive fungal isolates collected from 48 hospitals worldwide during the years 2018, 2019, and 2020. The findings showed that the COVID-19 pandemic had an impact on the occurrence and susceptibility rates of common fungal species.
Article
Microbiology
Dee Shortridge, Jennifer M. Streit, Rodrigo Mendes, Mariana Castanheira
Summary: Cefiderocol is a broad-spectrum cephalosporin with activity against Gram-negative bacteria, making it a valuable therapeutic option for drug-resistant infections.
MICROBIOLOGY SPECTRUM
(2022)
Article
Microbiology
A. Goer, L. S. Blanchard, A. Van Belkum, K. J. Loftus, T. P. Armstrong, S. G. Gatermann, D. Shortridge, B. J. Olson, J. K. Meece, T. R. Fritsche, M. Pompilio, D. Halimi, C. Franceschi
Summary: This study redeveloped and evaluated the fosfomycin strip, which showed good clinical performance against various pathogens, making it a potential substitute for the traditional method.
JOURNAL OF CLINICAL MICROBIOLOGY
(2022)
Article
Infectious Diseases
Dee Shortridge, Jennifer Streit, Michael Pfaller, Merrin Tulloch, Wei -Ting Chen, Mariana Castanheira
Summary: The study analyzed the susceptibility of Gram-negative isolates to C-T, showing that C-T is potent against Pseudomonas aeruginosa and Enterobacterales, including multi-drug resistant and extensively drug resistant isolates.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Article
Microbiology
Dee Shortridge, Valerie Kantro, Mariana Castanheira
Summary: Carbapenems are commonly used for Gram-negative infections, but carbapenem-resistant Enterobacterales (CRE) is a major concern. Klebsiella pneumoniae serine carbapenemases (KPCs) and metallo-beta-lactamases (MBLs) are prevalent globally. Meropenem-vaborbactam, an inhibitor of serine carbapenemases, showed high susceptibility in U.S. MDR Enterobacterales isolates. KPC was the most common carbapenemase, while MBL and OXA-48-like carbapenemases were less common.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
Cecilia G. G. Carvalhaes, Dee Shortridge, Leah N. N. Woosley, Nabina Gurung, Mariana Castanheira
Summary: This study evaluated the performance of the Vitek 2 Advanced Expert System (AES) confidence level report as a rapid tool for reporting antimicrobial susceptibility testing (AST) results for Enterobacterales isolates. The results showed that the AES assessment was accurate and enabled rapid adjustments to antimicrobial therapy.
MICROBIOLOGY SPECTRUM
(2023)
Article
Oncology
M. A. Pfaller, R. E. Mendes, H. S. Sader, M. Castanheira, C. G. Carvalhaes
Summary: Oritavancin demonstrated potent activity against clinically relevant Gram-positive pathogens in European hospitals, with minimal differences in minimum inhibitory concentration (MIC) values and varying resistance phenotypes between Eastern and Western Europe.
JOURNAL OF CHEMOTHERAPY
(2023)
Article
Microbiology
Mariana Castanheira, Timothy B. Doyle, Cory M. Hubler, Sean DeVries, Dee Shortridge
Summary: This study investigates the resistance mechanisms in Pseudomonas aeruginosa clinical isolates, which show higher meropenem MIC values compared to meropenem-vaborbactam. The results indicate that the overexpression of MexXY and AmpC, as well as the mutation in the AmpC gene, contribute to the lower meropenem-vaborbactam susceptibility in these isolates.
Article
Microbiology
Michael A. Pfaller, Dee Shortridge, Cecilia G. Carvalhaes, Mariana Castanheira
Summary: The study analyzed the susceptibility of contemporary ACB and SM isolates to different antibiotics and found that MIN is an effective treatment option for infections caused by ACB and SM.
MICROBIOLOGY SPECTRUM
(2023)